Etofenamate, a nonsteroidal anti-inflammatory drug (NSAID), was developed in the 1970s and introduced for medical use as a topical and injectable agent to treat pain and inflammation associated with musculoskeletal disorders. Its history is marked by its effectiveness in relieving joint and soft tissue inflammation, while minimizing systemic adverse effects compared to traditional oral NSAIDs. Etofenamate works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins, which are key mediators of pain, inflammation, and swelling.
BRAND NAMES
Rheumon – commonly used in topical gels and creams.
Traumalix – available as a topical formulation for joint and muscle pain.
MECHANISM OF ACTION
Etofenamate is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its effects by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes are responsible for the conversion of arachidonic acid to prostaglandins.
PHARMACOKINETICS
Absorption
Etofenamate is rapidly absorbed when applied topically to the skin, allowing for localized therapeutic effects at the site of inflammation or injury. Its absorption is influenced by factors such as skin integrity, thickness, and the area of application.
Distribution
etofenamate is widely distributed in body tissues, particularly in inflamed and musculoskeletal tissues, which contributes to its targeted anti-inflammatory effects. The drug is highly protein-bound in plasma, approximately 99%, which helps maintain tissue concentrations while limiting free systemic levels.
Metabolism
Etofenamate is extensively metabolized in the liver following systemic absorption. It undergoes hydrolysis and oxidation to form inactive metabolites. The liver metabolism helps reduce systemic exposure and contributes to the drug’s short systemic half-life.
Elimination
Etofenamate and its metabolites are primarily excreted via the kidneys in the urine, with a small amount eliminated in the feces. The drug has a relatively short elimination half-life, which supports frequent topical or systemic dosing to maintain therapeutic effects.
PHARMACODYNAMICS
Etofenamate is a nonsteroidal anti-inflammatory drug (NSAID) that produces analgesic, anti-inflammatory, and antipyretic effects primarily by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes. This inhibition reduces prostaglandin synthesis, which are key mediators of pain, inflammation, and swelling in injured or inflamed tissues.
ADMINISTRATION
Etofenamate is primarily administered topically in the form of gels, creams, or lotions applied directly to the affected area. The drug should be applied 2–3 times daily, depending on the severity of symptoms and the prescribing instructions. Before application, the skin should be clean and intact, and a thin layer should be gently massaged over the affected site.
DOSAGE AND STRENGTH
Etofenamate is commonly available in topical formulations, such as 5–10% gels, creams, or lotions, intended for application directly to inflamed or painful areas. The usual adult dosage involves applying a thin layer to the affected site 2–3 times daily, with the exact frequency determined by the severity of symptoms and the prescribing instructions.
DRUG INTERACTIONS
Etofenamate can interact with several medications, primarily due to its effects on renal function, platelet activity, and gastrointestinal integrity. Concomitant use with anticoagulants such as warfarin or heparin may increase the risk of bleeding, while combining etofenamate with other NSAIDs or corticosteroids can heighten the likelihood of gastrointestinal irritation or ulceration.
FOOD INTERACTIONS
Etofenamate, when used topically, has minimal to no food interactions, as systemic absorption is very limited. For oral or injectable formulations (available in some countries), taking the drug with food may help reduce gastrointestinal irritation, which is a common concern with NSAIDs.
CONTRAINDICATIONS
Etofenamate is contraindicated in patients with known hypersensitivity to etofenamate, other NSAIDs, or any component of the formulation. It should not be used in individuals with active gastrointestinal bleeding, peptic ulcers, or a history of NSAID-induced gastrointestinal complications, as it may exacerbate these conditions.
SIDE EFFECTS
Skin reactions: redness, itching, rash, burning, or irritation at the site of application
Gastrointestinal effects: nausea, dyspepsia, or abdominal discomfort (mainly with systemic use)
Allergic reactions: urticaria, hives, or hypersensitivity (rare)
Central nervous system: dizziness, headache (uncommon)
Renal effects: potential impairment with prolonged systemic use
OVER DOSAGE
Overdosage of etofenamate, especially with oral or injectable forms, can result in systemic toxicity affecting multiple organ systems. Symptoms may include nausea, vomiting, abdominal pain, gastrointestinal bleeding, dizziness, headache, hypotension.
TOXICITY
Toxicity from etofenamate is generally uncommon with topical use due to limited systemic absorption, but excessive or prolonged application can lead to local skin reactions such as redness, itching, burning, or dermatitis. Systemic toxicity is more likely with oral or injectable forms and may include gastrointestinal irritation, bleeding, renal impairment, and central nervous system effects such as dizziness or headache.
